Bluejay Diagnostics Inc (BJDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has a cash flow conversion efficiency ratio of -0.380x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Bluejay Diagnostics Inc for the company's overall valuation and market capitalisation.
Bluejay Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bluejay Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluejay Diagnostics Inc ranked by their cash flow conversion efficiency. See BJDX operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Setubandhan Infrastructure Limited
NSE:SETUINFRA
|
0.000x |
|
Upgrade Invest Nordic AB
ST:UPGRAD
|
N/A |
|
Insplorion AB
ST:INSP
|
-0.139x |
|
Hansard Global Plc
LSE:HSD
|
-0.013x |
|
Carr's Group plc
LSE:CARR
|
0.075x |
|
MAPSPEOPLE A/S DK-02
F:70R
|
N/A |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
0.988x |
|
Colefax Group
LSE:CFX
|
0.297x |
Annual Cash Flow Conversion Efficiency for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bluejay Diagnostics Inc from 2019 to 2025. View Bluejay Diagnostics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.98 Million | $-6.05 Million | -1.013x | +25.77% |
| 2024-12-31 | $5.73 Million | $-7.82 Million | -1.365x | +52.48% |
| 2023-12-31 | $2.89 Million | $-8.31 Million | -2.872x | -328.15% |
| 2022-12-31 | $11.54 Million | $-7.74 Million | -0.671x | -213.08% |
| 2021-12-31 | $20.38 Million | $-4.37 Million | -0.214x | -277.15% |
| 2020-12-31 | $-4.21 Million | $-508.71K | 0.121x | -79.02% |
| 2019-12-31 | $-2.93 Million | $-1.69 Million | 0.576x | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more